Trial Profile

Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexpramipexole (Primary)
Indications Eosinophilia; Nasal polyps; Sinusitis
Focus Therapeutic Use
Sponsors Knopp Biosciences

Most Recent Events

09 Jul 2019 According to an Knopp Biosciences media release, an overview data of the eosinophil-lowering effects of dexpramipexole observed in this study will be presented at the 11th Biennial Symposium of the International Eosinophil Society.
07 Mar 2017 According to a Knopp Biosciences media release, results from this study were presented at 2017 American Academy of Allergy and Immunology (AAAAI).
07 Mar 2017 Results published in the Knopp Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com